$27.25▴ 0.66%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-359.38MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-94.2%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
Beam Therapeutics Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year. Very low debt relative to its asset base.
Key numbers
Valuation
EPS (TTM)$-0.68
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-54.7%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$156.03M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.